Axsome Therapeutics (NASDAQ:AXSM) Given New $195.00 Price Target at Mizuho

Axsome Therapeutics (NASDAQ:AXSM) had its price objective boosted by Mizuho from $137.00 to $195.00 in a report released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a report on Monday. Robert W. Baird boosted their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Truist Financial raised their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $145.80.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $132.20 on Tuesday. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.19. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a 50-day moving average price of $95.28 and a 200-day moving average price of $92.07. The firm has a market capitalization of $6.41 billion, a PE ratio of -20.25 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the previous year, the business earned ($1.32) earnings per share. As a group, equities research analysts forecast that Axsome Therapeutics will post -4.7 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Assetmark Inc. purchased a new position in Axsome Therapeutics in the fourth quarter worth $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth $64,000. KBC Group NV grew its stake in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after buying an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares in the last quarter. Finally, Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics in the third quarter valued at about $200,000. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.